Department of Internal Medicine IV, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Institute of Pathology, University of Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
BMC Gastroenterol. 2019 Aug 27;19(1):153. doi: 10.1186/s12876-019-1075-0.
Primary sclerosing cholangitis is a chronic cholestatic liver disease. The pathomechanism is still not fully understood, but there is evidence that immune-mediated processes may contribute to disease progression.
We studied the prognostic relevance of serum immunoglobulin G (IgG) elevated above the upper limit of normal as a marker for immune activation at initial diagnosis and its influence on transplantation-free survival in a well-defined cohort of PSC patients.
The final study cohort comprises of 148 PSC patients. Elevated IgG levels were found in 66 patients (44.6%). Apart from their younger age at first diagnosis, there was no significant difference between patients with or without elevated IgG levels. The presence of a concomitant inflammatory bowel disease, an autoimmune hepatitis or immunosuppressive medication was equally distributed between both groups. Patients with elevated IgG levels reached the combined endpoint (34 (59.6%) vs. 23 (40.4%); p = 0.004) significantly more often and had reduced transplantation-free survival (Log-rank: 24.0 (10.2-37.9) vs. 14.0 (8.5-19.5); p < 0.05). Cox regression analysis including age, gender, presence of IBD, presence of dominant stricture (DS), Mayo Risk Score (MRS), immunosuppression, biochemical response to UDCA and elevated IgG-levels confirmed MRS (p = 0.03), DS (p = 0.04), biochemical response (p = 0.04) and elevated IgG level (p = 0.04) as independent risk factors for reduced transplantation-free survival.
We identified elevated serum IgG levels at first diagnosis as an independent risk factor for reduced transplant free-survival in patients with PSC.
原发性硬化性胆管炎是一种慢性胆汁淤积性肝病。其发病机制尚未完全阐明,但有证据表明免疫介导的过程可能导致疾病进展。
我们研究了初始诊断时血清免疫球蛋白 G(IgG)升高超过正常值上限作为免疫激活标志物的预后相关性及其对 PSC 患者无移植生存的影响,在一个明确的 PSC 患者队列中进行了研究。
最终研究队列包括 148 名 PSC 患者。66 名(44.6%)患者 IgG 水平升高。除了首次诊断时年龄较小外,IgG 水平升高和不升高的患者之间没有显著差异。两组之间同时存在炎症性肠病、自身免疫性肝炎或免疫抑制药物的比例相同。IgG 水平升高的患者更常达到联合终点(34 例[59.6%]比 23 例[40.4%];p=0.004),无移植生存时间明显缩短(对数秩检验:24.0(10.2-37.9)比 14.0(8.5-19.5);p<0.05)。包括年龄、性别、IBD 存在、主要狭窄(DS)存在、Mayo 风险评分(MRS)、免疫抑制、UDCA 生化反应和 IgG 水平升高在内的 Cox 回归分析证实,MRS(p=0.03)、DS(p=0.04)、生化反应(p=0.04)和 IgG 水平升高(p=0.04)是无移植生存时间缩短的独立危险因素。
我们发现 PSC 患者初始诊断时血清 IgG 水平升高是无移植生存时间缩短的独立危险因素。